Loading...
•
Dec 31, 2019
Trevena Q4 2019 Earnings Report
Trevena reported financial results for Q4 2019 and provided an overview of its 2019 and 2020 year-to-date operational highlights.
Key Takeaways
Trevena reported a net loss attributable to common stockholders of $6.4 million, or $0.07 per share, for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities were $35.8 million at December 31, 2019.
FDA acknowledged receipt of the resubmitted NDA for IV Oliceridine with a PDUFA goal date set for August 7, 2020.
Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734).
Announced NIH collaboration to evaluate TRV045 for epilepsy.
Updated guidance on extended cash runway, funding operations into Q1 2021.
Forward Guidance
Trevena believes that its cash and cash equivalents and marketable securities as of December 31, 2019, together with interest thereon, to be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the first quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...